

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

10/521 313

Application Number	Unknown
Confirmation Number	Unknown
Filing Date	January 14, 2005
First Named Inventor	Joon Youb LEE
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q85741

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation ⁶
KKH		L. Urbanelli et al., "Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage", <i>Journal of Molecular Biology</i> , Vol. 313, No. 5, (2001), pp. 965-976			
		L. Coussens et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with new oncogene", <i>Science</i> , Vol. 230, No. 4730, (1985), pp. 1132-1139			
		T. Yamamoto et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor", <i>Nature</i> , Vol. 319, No. 6050, pp. 230-234 (1986)			
		<i>Cancer Research</i> , Vol. 60, (2000), pp. 5228-5236			
		<i>Int. J. Cancer</i> , Vol. 81, (1999), pp. 748-754			
		<i>Cancer Research</i> , Vol. 58 (1998), pp. 1965-1971			
		<i>J. Immunol.</i> , Vol. 167, (2001), pp. 3201-3206			

Examiner Signature	Kevin K. Hill	Date Considered	Mar. 26, 2007
--------------------	---------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov. MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.



MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO

MAR 3 0 2005

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of 1

Complete if Known

Application Number	10/521,313
Confirmation Number	Unknown
Filing Date	January 14, 2005
First Named Inventor	Joon Youb LEE
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q85741

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
KKH		Tetsu AKIYAMA et al.; "The Product of the Human c-erbB-2 Gene: A 185-Kilodalton Glycoprotein With Tyrosine Kinase Activity"; Science Article; Vol. 232; 27 June 1986; pp. 1644-1646.	
		Dennis J. SLAMON et al.; "Human Breast Cancer: Correlation of Relapse and Survival With Amplification of the HER-2/neu Oncogene"; Science Articles; Vol. 235; 9 January 1987; pp. 177-182.	
		Michael S. EWER et al.; "Cardiotoxicity in Patients Receiving Trastuzumab (Herceptin): Primary Toxicity, Synergistic or Sequential Stress, or Surveillance Artifact"; Seminars in Oncology; Vol. 26; No. 4; Suppl. 12 (August) 1999; pp. 96-101.	
		Hiroya KOBAYASHI et al.; "Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen"; Cancer Research 60; September 15, 2000; pp. 5228-5236.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/521,313
Confirmation Number	9295
Filing Date	January 14, 2005
First Named Inventor	Joon Youb LEE
Art Unit	1646
Examiner Name	Unknown
Attorney Docket Number	Q85741

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
KKH		W. Wei et al., "Protection against mammary tumor growth by vaccination with full-length, Modified human ErbB-2 DNA", In Journal of Cancer, Vol. 81, 1999, pp. 748-754.	
	Dup.	L. Urbaneli et al., "Targeted Gene Transduction of Mammalian Cells Expressing the HER2/neu Receptor by Filamentous Phage", In Journal of Molecular Biology, Vol. 313, No. 5, 2001, pp. 965-976.	
	Dup.	L. Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene", In Science, Vol. 230, No. 4730, 1985, pp. 1132-1139.	
	Dup.	T. Yamamoto et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor", In Nature, Vol. 319, No. 6050, 1986, pp. 230-234.	
KKH		Y. Chen et al., "DNA Vaccines Encoding Full-Length or Truncated Neu Induce Protective Immunity against Neu-expressing Mammary Tumors", In Cancer Research, Vol. 58, 1998, pp. 1965-1971.	
KKH		S. Pilon et al., "Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB2-2 antibody", In Journal of Immunology, Vol. 167, 2001, pp. 3201-3206.	

Examiner Signature	Kevin K. Hill	Date Considered	Mar. 26, 2007
--------------------	---------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov. MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.